Asparaginase Erwinia chrysanthemi (Erwinaze)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Depletes plasma asparagine by catalyzing the deamidation of asparagine to aspartic acid and ammonia, selectively killing leukemic cells which are unable to synthesize asparagine due to a lack of asparagine synthetase.[1][2][3]
Route: IM
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Generic names: crisantaspasum, crisantaspase, Erwinia L-asparginase, krisantaspaasi, krisantaspas
  • Brand names: Erwinase, Erwinaze

References

  1. 1.0 1.1 1.2 Asparaginase Erwinia chrysanthemi (Erwinaze) package insert
  2. Asparaginase Erwinia chrysanthemi (Erwinaze) package insert (locally hosted backup)
  3. Erwinaze manufacturer's website
  4. Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (Chemocare)
  5. Asparaginase Erwinia chrysanthemi (Erwinaze) patient drug information (UpToDate)